[Stenoptin in angina pectoris (author's transl)].

Abstract

In a placebo-controlled double blind study 20 patients suffering from angina pectoris were treated with Stenoptin. The patients had 5 attacks at least per week and consumed 5 chwable nitrocapsules and more. Criteria of success were consumption of chewable nitrocapsules and frequency of attacks. During a 7 day preobservation period the patients received a placebo identical with Stenoptin and 20 chewable nitrocapsules. The study lasted for 8 weeks. The dose was 1 tablet 3 times per day. The attacks of the active substance group were reduced from 11 to 2 on the average, and the nitro-consumption from 16 to 2 per week. In the placebo group frequency of attack slightly increased from 10 to 11. In the active substance group the dose could be reduced to 1 tablet twice per day. The placebo group was treated with 1 Stenoptin tablet 3 times per day for another 8 weeks. Subsequently 1 tablet twice per day sufficed. Transient, nitro-induced headache occurred only in 3 test persons. Stenoptin did not cause side effects and was very effective in serious types of angina pectoris.

• Authors: M Adjan
• Journal: Medizinische Klinik (Med Klin) Vol. 73 Issue 26 Pg. 987-9 (Jun 30 1978) ISSN: 0025-8458 [Print] Germany
• Vernacular Title: Stenoptin bei Angina pectoris.
• PMID: 353461 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Nitro Compounds
• Verapamil
• Isosorbide Dinitrate
• Calcium

Topics

• Adult
• Aged
• Angina Pectoris (drug therapy, metabolism)
• Calcium (antagonists & inhibitors)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Isosorbide Dinitrate (therapeutic use)
• Male
• Middle Aged
• Nitro Compounds (therapeutic use)
• Oxygen Consumption
• Verapamil (therapeutic use)